股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | FF301 | 2. 股份分類 | 普通股 | 股份類別 | A ...

Group 1 - Shanghai Pharmaceuticals Holdings Co., Ltd. ranked 407th in the 2025 Fortune Global 500 list, marking its sixth consecutive year on the list [2] - In the 2025 Fortune China 500 list, Shanghai Pharmaceuticals ranked 98th, second among pharmaceutical companies [2] - The company achieved a revenue of 275.25 billion yuan in 2024, a year-on-year increase of 5.75%, and a net profit of 4.55 billion yuan, up 20.82% year-on-year [2] Group 2 - In the pharmaceutical manufacturing sector, Shanghai Pharmaceuticals operates production bases in 12 provinces and cities in China and overseas, producing around 800 drug specifications [2] - The company has 54 new drug pipelines that have received clinical trial application acceptance as of the end of 2024 [2] - The company has 44 products with industrial sales exceeding 100 million yuan, including 2 products exceeding 1 billion yuan [2] Group 3 - In the pharmaceutical commercial sector, Shanghai Pharmaceuticals' distribution network covers all 31 provinces, municipalities, and autonomous regions in China [3] - The company aims to strengthen commercial innovation and deepen the CSO model, collaborating with multinational pharmaceutical companies for innovative drug promotion [3] - The commercial sales revenue is expected to exceed 250 billion yuan for the first time in 2024 [3] Group 4 - Shanghai Pharmaceuticals is actively expanding into international markets, using Hong Kong as a base to register and launch traditional Chinese medicine [3] - The company is accelerating its expansion into Southeast Asia and the Middle East, enhancing the global influence of Chinese pharmaceutical brands [3] Group 5 - Looking ahead, Shanghai Pharmaceuticals aims to strengthen its role as a "chain leader" and enhance its core competitiveness, striving to become a world-class enterprise [4] - The company plans to implement a development system focused on "solidifying the foundation, strengthening the core, and innovating breakthroughs" [4]

Core Insights - Shanghai Pharmaceuticals Holding Co., Ltd. ranked 407th in the 2025 Fortune Global 500 list, marking its sixth consecutive year on the list, reflecting its sustainable development and enhanced core competitiveness [2] - In the 2025 Fortune China 500 list, the company ranked 98th, second among pharmaceutical companies, showcasing its strong position in the industry [4] Financial Performance - For the full year of 2024, the company achieved a revenue of RMB 275.25 billion, a year-on-year increase of 5.75%, and a net profit attributable to shareholders of RMB 4.55 billion, up 20.82% year-on-year [4] - In the first half of 2025, the company expects to achieve a net profit attributable to shareholders of approximately RMB 4.45 billion, representing a year-on-year growth of about 52% [4] Industrial and Commercial Operations - The pharmaceutical manufacturing segment operates production bases in 12 provinces in China and overseas, producing around 800 drug specifications and over 30 dosage forms, with multiple products certified by WHO, FDA, and EU [5] - The commercial segment has a distribution network covering all 31 provinces in China, with commercial sales revenue exceeding RMB 250 billion for the first time in 2024, driven by network expansion and management integration [5] Research and Development - The company has 54 new drug candidates in clinical trial stages, including 40 innovative drugs and 14 modified new drugs, with 44 products generating over RMB 100 million in sales, including 2 products exceeding RMB 1 billion [5] International Expansion - Shanghai Pharmaceuticals is actively expanding into international markets, using Hong Kong as a base to register and launch traditional Chinese medicine, while also targeting Southeast Asia and the Middle East to enhance the global influence of Chinese pharmaceutical brands [5] Future Outlook - The company aims to strengthen its role as a "chain leader" enterprise, focusing on solidifying its foundation, enhancing core capabilities, and driving innovation, with a goal of becoming a world-class enterprise and contributing to global health [5]

Group 1 - The latest Fortune Global 500 list includes 130 Chinese companies, with 12 headquartered in Shanghai [1] - Pinduoduo has shown rapid revenue growth, ranking as the fastest rising Chinese company on the list, moving from 442nd to 266th place, an increase of 176 positions [1] - Pinduoduo's total revenue for 2024 reached 393.84 billion yuan, a year-on-year increase of 59%, driven by a significant rise in transaction service revenue [1] Group 2 - Pinduoduo topped the Chinese companies' ROE (Return on Equity) ranking, with a net profit of 112.44 billion yuan, a substantial increase of 87% year-on-year [2] - China Pacific Insurance also saw a notable rise in ranking, moving from 331st to 251st, with a revenue of 404.09 billion yuan, up 24.7% year-on-year [2] - Other Shanghai-based companies on the list include China Baowu, SAIC Motor, and COSCO Shipping, with several having been on the list for over a decade [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 申请事项：境内生产药品注册临床试验 证券代码：601607 证券简称：上海医药 编号：临2025-076 上海医药集团股份有限公司 关于B019新适应症获得临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下属上海医药集团生物治疗技术有 限公司（以下简称"上药生物治疗"）自主研发的"B019"（以下简称"B019注射液"或"该项目"）收到国家 药品监督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》，同意其开展难治 性系统性红斑狼疮（以下简称"新适应症"）的临床试验。现将有关情况公告如下： 一、该项目基本信息 药物名称：靶向CD19和CD22 的嵌合抗原受体自体T细胞注射液 剂型：注射剂 受理号：CXSL2500344 通知书编号：2025LP01884 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年04月29日受理的靶向 CD19和CD2 ...

证券代码：601607 证券简称：上海医药 编号：临2025-076 上海医药集团股份有限公司 关于 B019 新适应症获得临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海医药集团生物治疗技术有限公司（以下简称"上药生物治疗"）自主研发 的"B019"（以下简称"B019 注射液"或"该项目"）收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》，同意其开 展难治性系统性红斑狼疮（以下简称"新适应症"）的临床试验。现将有关情况 公告如下： 一、该项目基本信息 药物名称：靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液 剂型：注射剂 申请事项：境内生产药品注册临床试验 受理号：CXSL2500344 通知书编号：2025LP01884 上海医药集团股份有限公司 二、该项目研发及注册情况 B019 注射液是靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液，拟用 ...

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Salbutamol Sulfate Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Salbutamol Sulfate Injection is primarily used for treating bronchial asthma or wheezing bronchitis and other respiratory diseases associated with bronchospasm [1]

格隆汇7月29日丨上海医药(601607.SH)公布，下属上海医药集团生物治疗技术有限公司（简称"上药生 物治疗"）自主研发的"B019"（简称"B019注射液"或"该项目"）收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，同意其开展难治性系统性红斑狼疮的临床试验。 ...

人民财讯7月29日电，上海医药（601607）7月29日晚间公告，公司下属上药生物治疗自主研发 的"B019"收到国家药监局核准签发的《药物临床试验批准通知书》，同意其开展难治性系统性红斑狼 疮(简称"新适应症")的临床试验。 ...